Gut microbiota - a double-edged sword in cancer immunotherapy
- PMID: 36088249
- DOI: 10.1016/j.trecan.2022.08.003
Gut microbiota - a double-edged sword in cancer immunotherapy
Abstract
Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many patients fail to respond to this therapy or experience side effects. Recently, gut microbiota have emerged as a key determinant of ICB efficacy and toxicity, making manipulation of the microbiome a novel therapeutic strategy with which to improve ICB outcomes.
Copyright © 2022 Elsevier Inc. All rights reserved.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical